On June 2, 2025, Reviva Pharmaceuticals announced successful completion of their Phase 3 RECOVER study, showing that brilaroxazine effectively treats schizophrenia with sustained efficacy over a year, while maintaining a low discontinuation rate of 35%. The study involved 446 patients across various doses and reported mild side effects, supporting brilaroxazine's safety profile.